Modulation of Growth Hormone-Releasing Activity of Hexarelin in Man
The DOI matches its Crossref record.
Abstract
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a new synthetic growth hormone (GH)-releasing hexapeptide. The mechanism of action of hexarelin in man is not fully elucidated. As for other GH-releasing peptides, an action on both the pituitary gland and the hypothalamus has been hypothesized. In the present study, we evaluated the modulation of GH-releasing activity of hexarelin in man. In a first experiment conducted on 6 healthy male volunteers, we studied the interaction of the maximally effective intravenous dose of hexarelin (2 µg/kg i.v.) with GH-releasing hormone (GHRH, 2 µg/kg i.v.) and somatostatin (2 µg/kg/h i.v.). In a second experiment involving another 6 male subjects, we evaluated the interaction of hexarelin with neuroactive substances, such as pirenzepine (0.6 mg/kg i.v.), pyridostigmine (120 mg p.o.) and arginine (0.5 g/kg i.v.), thought to modulate endogenous somatostatin secretion. Hexarelin induced a higher increase in GH levels as compared to GHRH (integrated output calculated as area under the curve AUC0-120 4,693 ± 691 vs. 1,494 ± 102 µg·min/l p < 0.01). Coadministration of hexarelin and GHRH produced a higher GH response than hexarelin alone (AUCo-120 7,395 ± 450 µg·min/1, p < 0.05). Somatostatin abolished the GH response to GHRH (AUC0–120 363 ± 89 µg·min/1, p < 0.01), while it only blunted that to hexarelin (AUCo-120 1,314 ± 297µg·min/l, p < 0.05). Pirenzepine blunted the GH response to hexarelin (AUC0–120 1,931 ± 446 vs. 4,586 ± 674 µg·min/1, p < 0.05) while pyridostigmine and arginine did not modify the GH response to the hexapeptide (AUC0–120 5,179 ± 771 and 4,743 ± 774 µg·min/1). Thus, the GH-releasing activity of hexarelin is greater than that of GHRH and is even enhanced by the neurohormone. Hexarelin differs from GHRH in that its effect is only blunted by exogenous somatostatin or pirenzepine and is not potentiated by pyridostigmine or arginine. These results indicate that, in man, hexarelin and GHRH may have different mechanisms of action and that the potent GH-releasing activity of hexarelin is partially refractory to modulation by somatostatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
van der Lely, A. J., Tschöp, M., Heiman, M. L., & Ghigo, E. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0029 · Cited by 1,187
Self-citationNeuroendocrine Control of Growth Hormone Secretion
Müller, E. E., Locatelli, V., & Cocchi, D. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.2.511 · Cited by 634
Iranmanesh, A., Bowers, C. Y., & Veldhuis, J. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0205 · Cited by 10
Metadata
- Authors
- Arvat, E., Gianotti, L., Di Vito, L., Imbimbo, B. P., Lenaerts, V., Deghenghi, R., Camanni, F., & Ghigo, E.
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 1995
- Volume
- 61
- Issue
- 1
- Pages
- 51-56
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2071165797
- Cited by
- 67
- References
- 0
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of Growth Hormone-Releasing Activity of Hexarelin in Man. https://app.cochat.ai/papers/10.1159/000126827
- The paper
- Arvat, E., Gianotti, L., Di Vito, L., Imbimbo, B. P., Lenaerts, V., Deghenghi, R., Camanni, F., & Ghigo, E. (1995). Modulation of Growth Hormone-Releasing Activity of Hexarelin in Man. Neuroendocrinology. https://doi.org/10.1159/000126827
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.